Researchers from Meiragtx Ltd. presented preclinical data on a new and optimized gene therapy based on a mini ATP7B gene for the potential treatment of Wilson’s disease (WD), a rare (1:30,000) autosomal recessive genetic disease caused by loss-of-function mutations in ATP7B, leading to a pathologically high amount of copper in the liver and brain.